453 Plasma metabolomic signature of novel signal transduction inhibitors from preclinical identification to clinical validation von Ang, J.E, Pandher, R, Asad, Y, Skene, D.J, Workman, P, Eccles, S, de Bono, J, Kaye, S, Banerji, U, Davies, S, Raynaud, F.I

Volltext

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer von Kolinsky, M.P., Rescigno, P., Bianchini, D., Zafeiriou, Z., Mehra, N., Mateo, J., Michalarea, V., Riisnaes, R., Crespo, M., Figueiredo, I., Miranda, S., Nava Rodrigues, D., Flohr, P., Tunariu, N., Banerji, U., Ruddle, R., Sharp, A., Welti, J., Lambros, M., Carreira, S., Raynaud, F.I., Swales, K.E., Plymate, S., Luo, J., Tovey, H., Porta, N., Slade, R., Leonard, L., Hall, E., de Bono, J.S.

Volltext

Discovery and validation of biomarkers to support clinical development of NXP800: A first-in-class orally active, small-molecule HSF1 pathway inhibitor von Workman, P., Clarke, P.A., Te Poele, R., Powers, M., Box, G., De Billy, E., De Haven Brandon, A., Hallsworth, A., Hayes, A., McCann, H., Sharp, S., Valenti, M., Raynaud, F.I., Eccles, S.A., Cheeseman, M., Jones, K.

Volltext

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer von Basu, B., Krebs, M.G., Sundar, R., Wilson, R.H., Spicer, J., Jones, R., Brada, M., Talbot, D.C., Steele, N., Ingles Garces, A.H., Brugger, W., Harrington, E.A., Evans, J., Hall, E., Tovey, H., de Oliveira, F.M., Carreira, S., Swales, K., Ruddle, R., Raynaud, F.I., Purchase, B., Dawes, J.C., Parmar, M., Turner, A.J., Tunariu, N., Banerjee, S., de Bono, J.S., Banerji, U.

Volltext

104 Plasma metabolomic analysis of genetic and pharmacological manipulation of PI 3-kinase pathway activation in mice using liquid chromatography coupled to mass spectrometry (LC-M... von Pandher, R, Ducruix, C, Box, G, Henley, A, Valenti, M, Brandon, A. De-Haven, Vanhaesebroeck, B, Workman, P, Eccles, S.A, Raynaud, F.I

Volltext

Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionization mass spectrometry von Poon, G.K., Raynaud, F.I., Mistry, P., Odell, D.E., Kelland, L.R., Harrap, K.R., Barnard, C.F.J., Murrer, B.A.

Volltext

Cross-platform Q-TOF validation of global exo-metabolomic analysis: Application to human glioblastoma cells treated with the standard PI 3-Kinase inhibitor LY294002 von Pandher, R., Ducruix, C., Eccles, S.A., Raynaud, F.I.

Volltext

118 POSTER Comparative pharmacokinetic study of abiraterone acetate in a capsule and tablet formulation von Raynaud, F.I, Martins, V, Yap, T, Carden, C, Jones, R.L, Riggs, S.B, Kabbinavar, F.F, McIntosh, D, Lee, G, De Bono, J.S

Volltext

Determination of metabolites of a novel platinum anticancer drug JM216 in human plasma ultrafiltrates von Poon, G.K., Mistry, P., Raynaud, F.I., Harrap, K.R., Murrer, B.A., Barnard, C.F.J.

Volltext

Selective FLT3 inhibition of [FLT3-ITD.sup.+] acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns von Moore, A.S, Faisal, A, de Castro, D. Gonzalez, Bavetsias, V, Sun, C, Atrash, B, Valenti, M, Brandon, A. de Haven, Avery, S, Mair, D, Mirabella, F, Swansbury, J, Pearson, A.D.J, Workman, P, Blagg, J, Raynaud, F.I, Eccles, S.A, Linardopoulos, S

Volltext

111 Development and validation of a mass spectrometric assay to evaluate drug-drug interaction in human liver microsomes. Application to anticancer agents von Raynaud, F.I., Moreno-Farre, J., Workman, P.

Volltext